Logo image of MRKR

MARKER THERAPEUTICS INC (MRKR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MRKR - US57055L2060 - Common Stock

1.49 USD
+0.07 (+4.93%)
Last: 12/9/2025, 5:28:39 PM
1.42 USD
-0.07 (-4.7%)
After Hours: 12/9/2025, 5:28:39 PM
Fundamental Rating

3

Overall MRKR gets a fundamental rating of 3 out of 10. We evaluated MRKR against 531 industry peers in the Biotechnology industry. The financial health of MRKR is average, but there are quite some concerns on its profitability. MRKR shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MRKR has reported negative net income.
In the past year MRKR has reported a negative cash flow from operations.
MRKR had negative earnings in each of the past 5 years.
MRKR had a negative operating cash flow in each of the past 5 years.
MRKR Yearly Net Income VS EBIT VS OCF VS FCFMRKR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of MRKR (-98.93%) is worse than 74.58% of its industry peers.
MRKR has a worse Return On Equity (-139.26%) than 63.84% of its industry peers.
Industry RankSector Rank
ROA -98.93%
ROE -139.26%
ROIC N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
MRKR Yearly ROA, ROE, ROICMRKR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRKR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRKR Yearly Profit, Operating, Gross MarginsMRKR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for MRKR has been increased compared to 1 year ago.
The number of shares outstanding for MRKR has been increased compared to 5 years ago.
MRKR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRKR Yearly Shares OutstandingMRKR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MRKR Yearly Total Debt VS Total AssetsMRKR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

MRKR has an Altman-Z score of -41.92. This is a bad value and indicates that MRKR is not financially healthy and even has some risk of bankruptcy.
MRKR has a Altman-Z score of -41.92. This is amonst the worse of the industry: MRKR underperforms 92.28% of its industry peers.
There is no outstanding debt for MRKR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -41.92
ROIC/WACCN/A
WACCN/A
MRKR Yearly LT Debt VS Equity VS FCFMRKR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 3.45 indicates that MRKR has no problem at all paying its short term obligations.
MRKR has a Current ratio (3.45) which is comparable to the rest of the industry.
A Quick Ratio of 3.45 indicates that MRKR has no problem at all paying its short term obligations.
MRKR has a Quick ratio of 3.45. This is comparable to the rest of the industry: MRKR outperforms 42.56% of its industry peers.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
MRKR Yearly Current Assets VS Current LiabilitesMRKR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

MRKR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.49%.
The Revenue has grown by 99.06% in the past year. This is a very strong growth!
MRKR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 99.23% yearly.
EPS 1Y (TTM)-28.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
Revenue 1Y (TTM)99.06%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%-35.98%

3.2 Future

The Earnings Per Share is expected to grow by 28.38% on average over the next years. This is a very strong growth
Based on estimates for the next years, MRKR will show a very strong growth in Revenue. The Revenue will grow by 95.82% on average per year.
EPS Next Y20.1%
EPS Next 2Y-19.32%
EPS Next 3Y2.53%
EPS Next 5Y28.38%
Revenue Next Year-62.2%
Revenue Next 2Y-41.04%
Revenue Next 3Y49.73%
Revenue Next 5Y95.82%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
MRKR Yearly Revenue VS EstimatesMRKR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MRKR Yearly EPS VS EstimatesMRKR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRKR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRKR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRKR Price Earnings VS Forward Price EarningsMRKR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRKR Per share dataMRKR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.32%
EPS Next 3Y2.53%

More info and screens

0

5. Dividend

5.1 Amount

MRKR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARKER THERAPEUTICS INC

NASDAQ:MRKR (12/9/2025, 5:28:39 PM)

After market: 1.42 -0.07 (-4.7%)

1.49

+0.07 (+4.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners20.7%
Inst Owner Change-0.78%
Ins Owners1.64%
Ins Owner Change0%
Market Cap24.84M
Revenue(TTM)6.59M
Net Income(TTM)-14.61M
Analysts84.44
Price Target8.33 (459.06%)
Short Float %1.85%
Short Ratio1.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.35%
Min EPS beat(2)28.04%
Max EPS beat(2)30.66%
EPS beat(4)3
Avg EPS beat(4)1.44%
Min EPS beat(4)-87.59%
Max EPS beat(4)34.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.41%
Min Revenue beat(2)-31.57%
Max Revenue beat(2)16.75%
Revenue beat(4)2
Avg Revenue beat(4)7.36%
Min Revenue beat(4)-44.56%
Max Revenue beat(4)88.82%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)48.91%
EPS NY rev (3m)55.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)18.6%
Revenue NY rev (3m)25.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.61
P/FCF N/A
P/OCF N/A
P/B 2.37
P/tB 2.37
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-1.71
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0.32
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -98.93%
ROE -139.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z -41.92
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
EPS Next Y20.1%
EPS Next 2Y-19.32%
EPS Next 3Y2.53%
EPS Next 5Y28.38%
Revenue 1Y (TTM)99.06%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%-35.98%
Revenue Next Year-62.2%
Revenue Next 2Y-41.04%
Revenue Next 3Y49.73%
Revenue Next 5Y95.82%
EBIT growth 1Y-33.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3378.79%
EBIT Next 3Y-137.86%
EBIT Next 5Y202.77%
FCF growth 1Y59.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.51%
OCF growth 3YN/A
OCF growth 5YN/A

MARKER THERAPEUTICS INC / MRKR FAQ

What is the fundamental rating for MRKR stock?

ChartMill assigns a fundamental rating of 3 / 10 to MRKR.


What is the valuation status for MRKR stock?

ChartMill assigns a valuation rating of 0 / 10 to MARKER THERAPEUTICS INC (MRKR). This can be considered as Overvalued.


Can you provide the profitability details for MARKER THERAPEUTICS INC?

MARKER THERAPEUTICS INC (MRKR) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for MRKR stock?

The Earnings per Share (EPS) of MARKER THERAPEUTICS INC (MRKR) is expected to grow by 20.1% in the next year.